Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.
Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.
Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses. These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.
Hospital Dr Josep Trueta, Girona, Spain
Faculty of Medicine, Tanta, Algharbia Governate, Egypt
Rabin Medical Center, Petah tikva, Israel
Atatürk University, Erzurum, Turkey
Ain Shams University Hospital, Cairo, EL Abassia, Egypt
University of Alberta Hospital, Edmonton, Alberta, Canada
CHRISTUS, Corpus Christi, Texas, United States
TWH/UHN, Toronto, Ontario, Canada
Medical School of Karadeniz Technical University, Department of Anesthesiology, Trabzon, Turkey
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.